PMID- 21273686
OWN - NLM
STAT- MEDLINE
DCOM- 20110810
LR  - 20200106
IS  - 2299-5684 (Electronic)
IS  - 1734-1140 (Linking)
VI  - 62
IP  - 6
DP  - 2010 Nov-Dec
TI  - Anti-inflammatory effect of atorvastatin in patients with aortic sclerosis or 
      mild aortic stenosis independent of hypercholesterolemia.
PG  - 1250-4
AB  - The aim of our study was to assess the effect of atorvastatin (20 mg) on 
      inflammatory biomarkers in patients with aortic sclerosis or mild aortic 
      stenosis. Additionally, the anti-inflammatory effect of statin therapy was 
      compared between hypercholesterolemic and non-hypercholesterolemic patients. We 
      enrolled 33 patients with aortic sclerosis or mild aortic stenosis (AS) (18 males 
      and 15 females, mean age 70 +/- 8 years). Plasma levels of the following biomarkers 
      were measured: C-reactive protein (CRP), interleukin (IL-6) and monocyte 
      chemoattractant protein-1 (MCP-1). Atorvastatin (20 mg) was used for four weeks. 
      All three biomarkers of inflammation significantly decreased after atorvastatin: 
      CRP from 4.08 +/- 3.72 to 2.97 +/- 3.26 mug/ml (p < 0.05), IL-6 from 20.66 +/- 20.05 to 
      13.36 +/- 11.21 pg/ml (p < 0.05) and MCP-1 from 271.08 +/- 85.72 to 213.24 +/- 115.09 
      pg/ml (p < 0.05). No differences in the levels of these biomarkers were shown in 
      a comparison between 17 patients with hypercholesterolemia and 16 patients 
      without hypercholesterolemia. In patients in the early stages of aortic valve 
      disease (with aortic sclerosis or mild AS), atorvastatin at a dose of 20 mg 
      reduced the biomarkers of inflammation.
FAU - Dimitrow, Pawel P
AU  - Dimitrow PP
AD  - 2nd Department of Cardiology, Collegium Medicum, Jagiellonian University, 
      Kopernika 17, PL 31-501 Krakow, Poland. dimitrow@mp.pl
FAU - Jawien, Marek
AU  - Jawien M
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Pharmacol Rep
JT  - Pharmacological reports : PR
JID - 101234999
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Biomarkers)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Heptanoic Acids)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Interleukin-6)
RN  - 0 (Pyrroles)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - A0JWA85V8F (Atorvastatin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Aorta/*pathology
MH  - Aortic Valve Stenosis/complications/*drug therapy
MH  - Atorvastatin
MH  - Biomarkers
MH  - C-Reactive Protein/analysis
MH  - Chemokine CCL2/analysis
MH  - Female
MH  - Heptanoic Acids/*therapeutic use
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Hypercholesterolemia/complications/*drug therapy
MH  - Interleukin-6/biosynthesis
MH  - Male
MH  - Pyrroles/*therapeutic use
MH  - Sclerosis
EDAT- 2011/01/29 06:00
MHDA- 2011/08/11 06:00
CRDT- 2011/01/29 06:00
PHST- 2010/01/26 00:00 [received]
PHST- 2010/05/15 00:00 [revised]
PHST- 2011/01/29 06:00 [entrez]
PHST- 2011/01/29 06:00 [pubmed]
PHST- 2011/08/11 06:00 [medline]
AID - S1734-1140(10)70390-X [pii]
AID - 10.1016/s1734-1140(10)70390-x [doi]
PST - ppublish
SO  - Pharmacol Rep. 2010 Nov-Dec;62(6):1250-4. doi: 10.1016/s1734-1140(10)70390-x.